Unique ID issued by UMIN | UMIN000003238 |
---|---|
Receipt number | R000003921 |
Scientific Title | Evaluation of Olmesartan on the Control of Morning Blood Pressure |
Date of disclosure of the study information | 2010/02/28 |
Last modified on | 2014/01/29 15:08:58 |
Evaluation of Olmesartan on the Control of Morning Blood Pressure
Evaluation of Olmesartan on the Control of Morning Blood Pressure
Evaluation of Olmesartan on the Control of Morning Blood Pressure
Evaluation of Olmesartan on the Control of Morning Blood Pressure
Japan |
Hypertension
Cardiology |
Others
NO
Olmesartan shows 12 to 18 hours duration of anti-hypertensive action. The long action of olmesartan may show the equivalent effect on blood pressure (BP) control despite of different time of taking the drug. If the control of BP is equivalent regardless of whether taking drug in the morning or evening, administration of drug is possible adapting patient's life style. We conducted this study to clarify the effect of BP control with home blood pressure measurement equipment between the groups taking in the morning and evening. Also we evaluate renin, angiotensin I, II, aldosterone, urinary albumin, and hs-CRP of both patients groups.
Efficacy
Confirmatory
Not applicable
Morning home blood pressure
renin, angiotensin, aldosterone,Urinary albumin, hs-CRP
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
YES
Institution is considered as a block.
Numbered container method
2
Treatment
Medicine |
Take medicine after breakfast
Take medicine after supper
15 | years-old | <= |
Not applicable |
Male and Female
Patient whose systolic blood pressure (BP) is over 140mmHg and/or diastolic BP is 90mmHg and not receives medication.
Exclusion criteria as follows: Patients who are pregnant or possibility of pregnancy, possess hypersensitivity to olmesartan, who are suffering from secondary hypertension, lateral or bilateral stenosis of renal arteries, cerebro-vascular diseases, hyper-potassemia, severe hepatic diseases, or elevated creatinine over 3.0mg/dl. Patient who are taking NSAID or steroids regularly, who are less than 15 years old, who are suffering from malignant neoplasm. Patients who are not selected by attendant physician.
236
1st name | |
Middle name | |
Last name | Hisao Mori, Yokohama Sotetsu bldg clinic of internal medicine |
Kanagawa Association of Medical and Dental Practitioners
Department of Clinical Research
TS plaza bldg 2 F, 2-23-2, tsuruya-Cho, Kanagawa-Ku, Yokohama, Japan
045-313-2111
hmori@gem.hi-ho.ne.jp
1st name | |
Middle name | |
Last name | Hisao Mori |
Kanagawa Association of Medical and Dental Practitioners
Department of Clinical Research
TS plaza bldg 2 F, 2-23-2, tsuruya-Cho, Kanagawa-Ku, Yokohama, Japan
045-313-2111
http://www.jinbokyo.com/research/index.html
hmori@gem.hi-ho.ne.jp
Kanagawa Association of Medical and Dental Practitioners
Kanagawa Association of Medical and Dental Practitioners
Other
Japan
NO
2010 | Year | 02 | Month | 28 | Day |
Published
Completed
2005 | Year | 09 | Month | 20 | Day |
2005 | Year | 09 | Month | 01 | Day |
2010 | Year | 02 | Month | 01 | Day |
2010 | Year | 02 | Month | 23 | Day |
2014 | Year | 01 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003921
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |